These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 27013879)

  • 1. The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials.
    Li G; Wang X; Ma D
    Neuropsychiatr Dis Treat; 2016; 12():523-31. PubMed ID: 27013879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Li G; Wang X; Ma D
    Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Εfficacy and safety of vortioxetine (Lu AA21004) in the treatment of adult patients with major depressive disorder: A systematic review and a meta‑analysis of randomized controlled trials.
    Gao S; Xie X; Fan L; Zhang D
    Exp Ther Med; 2023 Nov; 26(5):515. PubMed ID: 37840562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
    Inoue T; Sasai K; Kitagawa T; Nishimura A; Inada I
    Psychiatry Clin Neurosci; 2020 Feb; 74(2):140-148. PubMed ID: 31725942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.
    Baldwin DS; Florea I; Jacobsen PL; Zhong W; Nomikos GG
    J Affect Disord; 2016 Dec; 206():140-150. PubMed ID: 27474960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Chen Y
    Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.
    Pae CU; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Serretti A
    J Psychiatry Neurosci; 2015 May; 40(3):174-86. PubMed ID: 25350320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of 10 mg/day vortioxetine compared to placebo for adult major depressive disorder: a meta-analysis.
    Zheng J; Wang Z; Li E
    Afr Health Sci; 2019 Mar; 19(1):1716-1726. PubMed ID: 31149002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older.
    Nomikos GG; Tomori D; Zhong W; Affinito J; Palo W
    CNS Spectr; 2017 Aug; 22(4):348-362. PubMed ID: 27869048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials.
    Berhan A; Barker A
    BMC Psychiatry; 2014 Sep; 14():276. PubMed ID: 25260373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, acceptability, and safety of adjunctive aripiprazole in treatment-resistant depression: a meta-analysis of randomized controlled trials.
    Luan S; Wan H; Zhang L; Zhao H
    Neuropsychiatr Dis Treat; 2018; 14():467-477. PubMed ID: 29445284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial.
    Inoue T; Nishimura A; Sasai K; Kitagawa T
    Psychiatry Clin Neurosci; 2018 Feb; 72(2):103-115. PubMed ID: 29160598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults.
    Thase ME; Mahableshwarkar AR; Dragheim M; Loft H; Vieta E
    Eur Neuropsychopharmacol; 2016 Jun; 26(6):979-93. PubMed ID: 27139079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Vortioxetine on Cognitive Impairment in Patients With Major Depressive Disorder: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Huang IC; Chang TS; Chen C; Sung JY
    Int J Neuropsychopharmacol; 2022 Dec; 25(12):969-978. PubMed ID: 35981958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of olanzapine/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials.
    Luan S; Wan H; Wang S; Li H; Zhang B
    Neuropsychiatr Dis Treat; 2017; 13():609-620. PubMed ID: 28280343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study.
    Wang J; Liu XF; Feng C; Bao Q; Fu HR
    Int J Psychiatry Clin Pract; 2019 Nov; 23(4):245-250. PubMed ID: 29113521
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma.
    Christensen MC; Florea I; Loft H; McIntyre RS
    J Affect Disord; 2020 Feb; 263():258-266. PubMed ID: 31818787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
    Christensen MC; Loft H; McIntyre RS
    J Affect Disord; 2018 Feb; 227():787-794. PubMed ID: 29689693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.